


# LabCorp offers the leading HCV menu for complete care decisions

Laboratory tests to aid in the screening, evaluation, and management of HCV include



# LabCorp offers the leading HCV menu for complete care decisions

LabCorp offers a comprehensive menu of HCV tests to aid in screening, diagnosis, prognosis, and monitoring of patients with hepatitis C virus (HCV).

**Our portfolio of HCV tests includes the following tests that are represented in the diagram on the previous page.** For complete test options, visit our online Test Menu at [www.LabCorp.com/testmenu](http://www.LabCorp.com/testmenu).

## Hepatitis C Virus (HCV) Antibody With Reflex to Qualitative NAA ..... 144045

HCV screening recommendations (AASLD, IDSA, ACG) include: anyone who has ever injected illegal drugs, people with HIV, anyone who received a blood transfusion or organ transplant prior to July 1992, children born to HCV-infected mothers, any health worker experiencing a needle-stick injury, and current sexual partners of HCV-infected people.<sup>1,2</sup>

- In August 2012, the Centers for Disease Control and Prevention (CDC) recommended that all “baby boomers” [people born from 1945-1965] be screened for HCV infection using an FDA-approved antibody test, with an FDA-approved NAT test (also called an HCV RNA test) performed on any specimens with a positive antibody result.<sup>1</sup>
- LabCorp offers test 144045—Hepatitis C Virus (HCV) Antibody With Reflex to Qualitative NAA—using FDA-approved antibody and NAT tests to aid in the screening and follow up of those who are indicated for HCV evaluation, including baby boomers under the CDC guidance. HCV antibody testing and HCV RNA testing may also be ordered individually.

## HCV, Quantitative, Real-time PCR (Nongraphical) ..... 550080

### HCV, Quantitative, Real-time PCR (Graphical) ..... 550070

- Quantifies patient’s viral load. Limit of detection is 15 IU/mL for all HCV genotypes, and the quantifiable range of the assay is 15 IU/mL to 100,000,000 IU/mL.
- Can provide a baseline assessment prior to therapy in treatment-naïve patients. Also used to monitor patients on therapy and posttherapy.<sup>1-5</sup>

## Hepatitis C Virus (HCV), Quantitative, RNA PCR (Nongraphical) With Reflex to Genotyping ..... 550090

### Hepatitis C Virus (HCV), Quantitative, RNA PCR (Graphical) With Reflex to Genotyping ..... 550100

- Quantifies patient’s viral load and allows genotyping of the six major HCV types.

## HCV Genotyping ..... 550475

- Allows genotyping of the six major HCV types and their most common subtypes.
- Genotype is important in determining which therapy and duration is most appropriate for the patient.<sup>1-5</sup>

## HCV FibroSure® ..... 550123

- Is a noninvasive blood test of 6 biochemical markers that provides METAVIR fibrosis staging and necroinflammatory grading.
- May be useful in defining the presence or absence of advanced fibrosis.<sup>2</sup>
- HCV FibroSure has been validated against liver biopsy, and has demonstrated diagnostic value comparable to liver biopsy in assessing fibrosis.<sup>9</sup>

## HCV GenoSure® NS3/4A ..... 550540

- Provides a comprehensive sequence-based analysis of drug resistance for HCV protease inhibitors (PIs), also known as direct-acting antivirals (DAAs).
- Detects mutations in NS3 and NS4A and identifies drug resistant variants for protease inhibitors paritaprevir, simeprevir, and grazoprevir.
- Aids clinicians in identifying drug resistance variants that may impact the efficacy of protease inhibitor therapy.<sup>2</sup>
- Identifies the Q80K polymorphism at baseline when considering a simeprevir-containing regimen.<sup>2,3</sup>

## Hepatitis C Virus (HCV) NS5A Drug Resistance Assay ..... 550325

- Assessment of drug susceptibility by nucleic acid sequencing of a patient’s HCV to the NS5A inhibitors including ledipasvir, ombitasvir, elbasvir, and daclatasvir.
- Assay should be used for patients with documented HCV genotype 1a or 1b.
- Recommended for patients with genotype 1 who were previously treated with a NS5A inhibitor and are being considered for retreatment.<sup>2</sup>

## Hepatitis C Virus (HCV) Genotype 3 NS5A Drug Resistance Assay ..... 550603

- Assessment of drug susceptibility by nucleic acid sequencing of a patient’s HCV to the NS5A inhibitors including daclatasvir.
- Assay should be used for patients with documented HCV genotype 3.

## Hepatitis C Virus (HCV) NS5B Drug Resistance Assay ..... 550505

- Assessment of drug susceptibility by nucleic acid sequencing of a patient’s HCV to the NS5B polymerase inhibitors including sofosbuvir and dasabuvir.
- Assay should be used for patients with documented HCV genotype 1a or 1b.

### References

1. Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. *MMWR* 2012;61 (No. RR-4):1-32.
2. American Association for the Study of Liver Diseases (AASLD); Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Hepatitis C. Available at <http://www.hcvguidelines.org>. Updated February 24, 2016. Accessed March 2, 2016.
3. Olysio (simeprevir) capsules, for oral use [Highlights of Prescribing Information]. Titusville, NJ: Janssen Therapeutics; 2013. Reference ID: 3412095.
4. Zepatier™ (elbasvir and grazoprevir) tablets, for oral use [package insert]. Initial US Approval: 2016. Whitehouse Station, NJ: Merck and Co Inc; 2016.
5. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use [package insert]. Foster City, Calif: Gilead Sciences Inc; October 2014.
6. SOVALDI™ (sofosbuvir) tablets, for oral use [package insert]. Foster City, Calif: Gilead Sciences Inc; December 2013.
7. Viekira PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use [Highlights of Prescribing Information], North Chicago, IL: AbbVie Inc; 2014.
8. DAKLINZA™ (daclatasvir) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Meyers Squibb; July 2015.
9. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. *BMC Gastro*. 2007 Oct 15;7:40.



[www.LabCorp.com](http://www.LabCorp.com)

DAKLINZA™ is a registered trademark of Bristol-Meyers Squibb  
Zepatier™ is a registered trademark of Merck and Co Inc  
Harvoni® is a registered trademark of Gilead Sciences Inc.  
Viekira Pak is a trademark of AbbVie Inc.  
Sovaldi® is a registered trademark of Gilead Sciences Inc.  
©2016 Laboratory Corporation of America® Holdings All rights reserved. L10589-0316-9